Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate
- 31 May 2006
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (5) , S229-S230
- https://doi.org/10.1016/j.jaad.2005.11.1037
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Management of multifocal primary cutaneous CD30+ anaplastic large cell lymphomaJournal of the American Academy of Dermatology, 2004
- Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (AldaraR)British Journal of Dermatology, 2004
- Cd30+ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphomaJournal of the American Academy of Dermatology, 2003
- Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatmentBlood, 2000
- Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhoodJournal of the American Academy of Dermatology, 1999
- Statistical Evaluation of Diagnostic and Prognostic Features of CD30+ Cutaneous Lymphoproliferative DisordersThe American Journal of Surgical Pathology, 1998
- Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disordersJournal of the American Academy of Dermatology, 1996
- Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: A proposal for classification and guidelines for management and treatmentJournal of the American Academy of Dermatology, 1993
- Treatment of keratoacanthomas with intralesional methotrexateJournal of the American Academy of Dermatology, 1991